题目：The pharmacogenomics of asparaginase immune responses: preventing and overcoming immunotoxicity.
报告人：Christian A. Fernandez，美国匹兹堡大学，教授
Dr. Fernandez earned his Ph.D. from the Department of Pharmaceutics at the University of Iowa, where his dissertation research concentrated on the development of PEGylated polyacridine peptides for in vivo gene delivery of plasmid DNA. In 2010, he joined the Department of Pharmaceutical Sciences at St. Jude Children’s Research Hospital under the mentorship of Mary Relling. His postdoctoral training was broad in context but uniformly directed towards improving the treatment of pediatric acute lymphoblastic leukemia. His projects included analyzing retrospective clinical trial data, performing genetic association analyses related to the adverse effects of medications used to treat leukemia, and creating murine models of adverse drug reactions. He joined the Center for Pharmacogenetics and the Department of Pharmaceutical Sciences at the University of Pittsburgh School of Pharmacy in 2015, where his current research interest include the adverse drug reactions to the chemotherapeutic agent, asparaginase, which is one of the essential agents used during the treatment of pediatric leukemias and lymphomas. Specifically, his research focuses on the immune response to asparaginase, which can decrease drug levels of asparaginase and lead to worse treatment outcome. His research aims are to identify patients that may be genetically predisposed to developing an immune response to the drug, to determine therapeutic strategies for preventing or managing the immune response, and to develop a clinical laboratory test that can identify asparaginase-sensitized patients prior to their next course of treatment.